Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas

A Gynecologic Oncology Group study

David Scott Miller, John A. Blessing, Larry Kilgore, Robert Mannel, Linda Van Le

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

From October 1995 to March 1997, a phase II trial of topotecan was carried out in chemotherapy-naive women with advanced, persistent, or recurrent uterine leiomyosarcomas. Thirty-six patients were entered. Median age was 53 years. Performance status was 0 (50%) in 18, 1 (36%) in 13, and 2 (14%) in 5. Most patients, 33 (92%), had undergone prior surgery, and 8 (22%) prior radiation therapy. Topotecan, 1.5 mg/m2, was administered intravenously daily for 5 days, every 3 weeks, until progression of disease or adverse affects prohibited further therapy. Patients received 1 to 13 courses with a median of 3 courses. The most frequent grade 4 adverse effects were neutropenia in 28 (78%), leukopenia in 8 (22%), thrombocytopenia in 3 (8%), and anemia in 3 (8%). Complete response was seen in 1 (3%), partial response in 3 (8%), stable disease in 12 (33%), and increasing tumor in 20 (56%). Thus topotecan at this dose and schedule does not appear to have major activity in uterine leiomyosarcomas.

Original languageEnglish (US)
Pages (from-to)355-357
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume23
Issue number4
DOIs
StatePublished - Dec 1 2000

Fingerprint

Topotecan
Leiomyosarcoma
Leukopenia
Neutropenia
Disease Progression
Anemia
Appointments and Schedules
Radiotherapy
Drug Therapy
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas : A Gynecologic Oncology Group study. / Miller, David Scott; Blessing, John A.; Kilgore, Larry; Mannel, Robert; Van Le, Linda.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 23, No. 4, 01.12.2000, p. 355-357.

Research output: Contribution to journalArticle

@article{ecd4e79f4ec647b6aaf81d9606f5c1ce,
title = "Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: A Gynecologic Oncology Group study",
abstract = "From October 1995 to March 1997, a phase II trial of topotecan was carried out in chemotherapy-naive women with advanced, persistent, or recurrent uterine leiomyosarcomas. Thirty-six patients were entered. Median age was 53 years. Performance status was 0 (50{\%}) in 18, 1 (36{\%}) in 13, and 2 (14{\%}) in 5. Most patients, 33 (92{\%}), had undergone prior surgery, and 8 (22{\%}) prior radiation therapy. Topotecan, 1.5 mg/m2, was administered intravenously daily for 5 days, every 3 weeks, until progression of disease or adverse affects prohibited further therapy. Patients received 1 to 13 courses with a median of 3 courses. The most frequent grade 4 adverse effects were neutropenia in 28 (78{\%}), leukopenia in 8 (22{\%}), thrombocytopenia in 3 (8{\%}), and anemia in 3 (8{\%}). Complete response was seen in 1 (3{\%}), partial response in 3 (8{\%}), stable disease in 12 (33{\%}), and increasing tumor in 20 (56{\%}). Thus topotecan at this dose and schedule does not appear to have major activity in uterine leiomyosarcomas.",
author = "Miller, {David Scott} and Blessing, {John A.} and Larry Kilgore and Robert Mannel and {Van Le}, Linda",
year = "2000",
month = "12",
day = "1",
doi = "10.1097/00000421-200008000-00009",
language = "English (US)",
volume = "23",
pages = "355--357",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas

T2 - A Gynecologic Oncology Group study

AU - Miller, David Scott

AU - Blessing, John A.

AU - Kilgore, Larry

AU - Mannel, Robert

AU - Van Le, Linda

PY - 2000/12/1

Y1 - 2000/12/1

N2 - From October 1995 to March 1997, a phase II trial of topotecan was carried out in chemotherapy-naive women with advanced, persistent, or recurrent uterine leiomyosarcomas. Thirty-six patients were entered. Median age was 53 years. Performance status was 0 (50%) in 18, 1 (36%) in 13, and 2 (14%) in 5. Most patients, 33 (92%), had undergone prior surgery, and 8 (22%) prior radiation therapy. Topotecan, 1.5 mg/m2, was administered intravenously daily for 5 days, every 3 weeks, until progression of disease or adverse affects prohibited further therapy. Patients received 1 to 13 courses with a median of 3 courses. The most frequent grade 4 adverse effects were neutropenia in 28 (78%), leukopenia in 8 (22%), thrombocytopenia in 3 (8%), and anemia in 3 (8%). Complete response was seen in 1 (3%), partial response in 3 (8%), stable disease in 12 (33%), and increasing tumor in 20 (56%). Thus topotecan at this dose and schedule does not appear to have major activity in uterine leiomyosarcomas.

AB - From October 1995 to March 1997, a phase II trial of topotecan was carried out in chemotherapy-naive women with advanced, persistent, or recurrent uterine leiomyosarcomas. Thirty-six patients were entered. Median age was 53 years. Performance status was 0 (50%) in 18, 1 (36%) in 13, and 2 (14%) in 5. Most patients, 33 (92%), had undergone prior surgery, and 8 (22%) prior radiation therapy. Topotecan, 1.5 mg/m2, was administered intravenously daily for 5 days, every 3 weeks, until progression of disease or adverse affects prohibited further therapy. Patients received 1 to 13 courses with a median of 3 courses. The most frequent grade 4 adverse effects were neutropenia in 28 (78%), leukopenia in 8 (22%), thrombocytopenia in 3 (8%), and anemia in 3 (8%). Complete response was seen in 1 (3%), partial response in 3 (8%), stable disease in 12 (33%), and increasing tumor in 20 (56%). Thus topotecan at this dose and schedule does not appear to have major activity in uterine leiomyosarcomas.

UR - http://www.scopus.com/inward/record.url?scp=0034445901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034445901&partnerID=8YFLogxK

U2 - 10.1097/00000421-200008000-00009

DO - 10.1097/00000421-200008000-00009

M3 - Article

VL - 23

SP - 355

EP - 357

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -